Potent Antipneumococcal Activity of Gemifloxacin Is Associated with Dual Targeting of Gyrase and Topoisomerase IV, an In Vivo Target Preference for Gyrase, and Enhanced Stabilization of Cleavable Complexes In Vitro
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue AAC About AAC Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commerc...
Gespeichert in:
| Veröffentlicht in: | Antimicrobial Agents and Chemotherapy 2000-11, Vol.44 (11), p.3112-3117 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3117 |
|---|---|
| container_issue | 11 |
| container_start_page | 3112 |
| container_title | Antimicrobial Agents and Chemotherapy |
| container_volume | 44 |
| creator | HEATON, Victoria J AMBLER, Jane E FISHER, L. Mark |
| description | Classifications
Services
AAC
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit
StumbleUpon
Twitter
current issue
AAC
About
AAC
Subscribers
Authors
Reviewers
Advertisers
Inquiries from the Press
Permissions & Commercial Reprints
ASM Journals Public Access Policy
AAC
RSS Feeds
1752 N Street N.W. • Washington DC 20036
202.737.3600 • 202.942.9355 fax • journals@asmusa.org
Print ISSN:
0066-4804
Online ISSN:
1098-6596
Copyright © 2014
by the
American Society for Microbiology.
For an alternate route to
AAC
.asm.org, visit:
AAC
|
| doi_str_mv | 10.1128/AAC.44.11.3112-3117.2000 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_72342314</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17640422</sourcerecordid><originalsourceid>FETCH-LOGICAL-a548t-e75ab3ee3568b515a6652facf567a61909a9627cfd2253bc8f3322f9bc8e04743</originalsourceid><addsrcrecordid>eNqNks9uEzEQxlcIREvhFZCFUE9N8L_1bg4colBKpEpUIvRqTZzZxNWuHWwnbXhQngdvEtFygos9Hn-_GWv8FQVhdMgYrz-Mx5OhlDkeinwe5KUackrps-KU0VE9UOVIPS9OKVVqIGsqT4pXMd5lQb6gL4sTxqhQVPDT4teNT-gSGbtk1w43nTfeGGjJ2CS7tWlHfEOusLNN6x_AWEemkYxj9MZCwgW5t2lFPm0yMIOwxGTdck_sAkQk4BZk5tfeRt_hPjO9vchZMnXk1m79ESI3ARsM6AySxocjfbHHL90Kcn5BviWY29b-hGS963tMWoQtzFskE9-tW3zAeKibgn9dvGigjfjmuJ8V3z9fziZfBtdfr6aT8fUASlmnAVYlzAWiKFU9L1kJSpW8AdOUqgLFRnQEI8Ur0yw4L8Xc1I0QnDejHCGVlRRnxcdD3fVm3uHC5FEGaPU62A7CTnuw-u8bZ1d66beaUaYYz_z5kQ_-xwZj0p2NBtsWHPpN1BUXkgsm_ylklZJU8r5ifRCa4GPMc_3zGEZ1bx6dzaOlzLHuzdMvle7Nk9HygELsuL7zm-Dy7P6He_t0CI8Njy7LgvdHAcTsrSbkH7XxUVcKXpW97N1BtrLL1b0NqPNDNIB50lb8BuKO6_o</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17640422</pqid></control><display><type>article</type><title>Potent Antipneumococcal Activity of Gemifloxacin Is Associated with Dual Targeting of Gyrase and Topoisomerase IV, an In Vivo Target Preference for Gyrase, and Enhanced Stabilization of Cleavable Complexes In Vitro</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>HEATON, Victoria J ; AMBLER, Jane E ; FISHER, L. Mark</creator><creatorcontrib>HEATON, Victoria J ; AMBLER, Jane E ; FISHER, L. Mark</creatorcontrib><description>Classifications
Services
AAC
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit
StumbleUpon
Twitter
current issue
AAC
About
AAC
Subscribers
Authors
Reviewers
Advertisers
Inquiries from the Press
Permissions & Commercial Reprints
ASM Journals Public Access Policy
AAC
RSS Feeds
1752 N Street N.W. • Washington DC 20036
202.737.3600 • 202.942.9355 fax • journals@asmusa.org
Print ISSN:
0066-4804
Online ISSN:
1098-6596
Copyright © 2014
by the
American Society for Microbiology.
For an alternate route to
AAC
.asm.org, visit:
AAC
</description><identifier>ISSN: 0066-4804</identifier><identifier>EISSN: 1098-6596</identifier><identifier>DOI: 10.1128/AAC.44.11.3112-3117.2000</identifier><identifier>PMID: 11036032</identifier><identifier>CODEN: AACHAX</identifier><language>eng</language><publisher>Washington, DC: American Society for Microbiology</publisher><subject>Anti-Infective Agents ; Anti-Infective Agents - pharmacology ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Biological and medical sciences ; Ciprofloxacin - pharmacology ; DNA Gyrase ; DNA Topoisomerase IV ; DNA Topoisomerases, Type II ; DNA Topoisomerases, Type II - drug effects ; DNA Topoisomerases, Type II - genetics ; DNA Topoisomerases, Type II - metabolism ; Drug Resistance, Microbial - genetics ; Fluoroquinolones ; Gemifloxacin ; gyrA gene ; Humans ; Mechanisms of Action: Physiological Effects ; Medical sciences ; Microbial Sensitivity Tests ; Mutation ; Naphthyridines ; Naphthyridines - pharmacology ; parC gene ; Pharmacology. Drug treatments ; Streptococcus pneumoniae ; Streptococcus pneumoniae - drug effects ; Streptococcus pneumoniae - enzymology ; Streptococcus pneumoniae - genetics</subject><ispartof>Antimicrobial Agents and Chemotherapy, 2000-11, Vol.44 (11), p.3112-3117</ispartof><rights>2000 INIST-CNRS</rights><rights>Copyright © 2000 American Society for Microbiology</rights><rights>Copyright © 2000, American Society for Microbiology 2000</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a548t-e75ab3ee3568b515a6652facf567a61909a9627cfd2253bc8f3322f9bc8e04743</citedby><cites>FETCH-LOGICAL-a548t-e75ab3ee3568b515a6652facf567a61909a9627cfd2253bc8f3322f9bc8e04743</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC101612/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC101612/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1532752$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11036032$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HEATON, Victoria J</creatorcontrib><creatorcontrib>AMBLER, Jane E</creatorcontrib><creatorcontrib>FISHER, L. Mark</creatorcontrib><title>Potent Antipneumococcal Activity of Gemifloxacin Is Associated with Dual Targeting of Gyrase and Topoisomerase IV, an In Vivo Target Preference for Gyrase, and Enhanced Stabilization of Cleavable Complexes In Vitro</title><title>Antimicrobial Agents and Chemotherapy</title><addtitle>Antimicrob. Agents Chemother</addtitle><addtitle>Antimicrob Agents Chemother</addtitle><description>Classifications
Services
AAC
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit
StumbleUpon
Twitter
current issue
AAC
About
AAC
Subscribers
Authors
Reviewers
Advertisers
Inquiries from the Press
Permissions & Commercial Reprints
ASM Journals Public Access Policy
AAC
RSS Feeds
1752 N Street N.W. • Washington DC 20036
202.737.3600 • 202.942.9355 fax • journals@asmusa.org
Print ISSN:
0066-4804
Online ISSN:
1098-6596
Copyright © 2014
by the
American Society for Microbiology.
For an alternate route to
AAC
.asm.org, visit:
AAC
</description><subject>Anti-Infective Agents</subject><subject>Anti-Infective Agents - pharmacology</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Ciprofloxacin - pharmacology</subject><subject>DNA Gyrase</subject><subject>DNA Topoisomerase IV</subject><subject>DNA Topoisomerases, Type II</subject><subject>DNA Topoisomerases, Type II - drug effects</subject><subject>DNA Topoisomerases, Type II - genetics</subject><subject>DNA Topoisomerases, Type II - metabolism</subject><subject>Drug Resistance, Microbial - genetics</subject><subject>Fluoroquinolones</subject><subject>Gemifloxacin</subject><subject>gyrA gene</subject><subject>Humans</subject><subject>Mechanisms of Action: Physiological Effects</subject><subject>Medical sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Mutation</subject><subject>Naphthyridines</subject><subject>Naphthyridines - pharmacology</subject><subject>parC gene</subject><subject>Pharmacology. Drug treatments</subject><subject>Streptococcus pneumoniae</subject><subject>Streptococcus pneumoniae - drug effects</subject><subject>Streptococcus pneumoniae - enzymology</subject><subject>Streptococcus pneumoniae - genetics</subject><issn>0066-4804</issn><issn>1098-6596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNks9uEzEQxlcIREvhFZCFUE9N8L_1bg4colBKpEpUIvRqTZzZxNWuHWwnbXhQngdvEtFygos9Hn-_GWv8FQVhdMgYrz-Mx5OhlDkeinwe5KUackrps-KU0VE9UOVIPS9OKVVqIGsqT4pXMd5lQb6gL4sTxqhQVPDT4teNT-gSGbtk1w43nTfeGGjJ2CS7tWlHfEOusLNN6x_AWEemkYxj9MZCwgW5t2lFPm0yMIOwxGTdck_sAkQk4BZk5tfeRt_hPjO9vchZMnXk1m79ESI3ARsM6AySxocjfbHHL90Kcn5BviWY29b-hGS963tMWoQtzFskE9-tW3zAeKibgn9dvGigjfjmuJ8V3z9fziZfBtdfr6aT8fUASlmnAVYlzAWiKFU9L1kJSpW8AdOUqgLFRnQEI8Ur0yw4L8Xc1I0QnDejHCGVlRRnxcdD3fVm3uHC5FEGaPU62A7CTnuw-u8bZ1d66beaUaYYz_z5kQ_-xwZj0p2NBtsWHPpN1BUXkgsm_ylklZJU8r5ifRCa4GPMc_3zGEZ1bx6dzaOlzLHuzdMvle7Nk9HygELsuL7zm-Dy7P6He_t0CI8Njy7LgvdHAcTsrSbkH7XxUVcKXpW97N1BtrLL1b0NqPNDNIB50lb8BuKO6_o</recordid><startdate>20001101</startdate><enddate>20001101</enddate><creator>HEATON, Victoria J</creator><creator>AMBLER, Jane E</creator><creator>FISHER, L. Mark</creator><general>American Society for Microbiology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20001101</creationdate><title>Potent Antipneumococcal Activity of Gemifloxacin Is Associated with Dual Targeting of Gyrase and Topoisomerase IV, an In Vivo Target Preference for Gyrase, and Enhanced Stabilization of Cleavable Complexes In Vitro</title><author>HEATON, Victoria J ; AMBLER, Jane E ; FISHER, L. Mark</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a548t-e75ab3ee3568b515a6652facf567a61909a9627cfd2253bc8f3322f9bc8e04743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Anti-Infective Agents</topic><topic>Anti-Infective Agents - pharmacology</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Ciprofloxacin - pharmacology</topic><topic>DNA Gyrase</topic><topic>DNA Topoisomerase IV</topic><topic>DNA Topoisomerases, Type II</topic><topic>DNA Topoisomerases, Type II - drug effects</topic><topic>DNA Topoisomerases, Type II - genetics</topic><topic>DNA Topoisomerases, Type II - metabolism</topic><topic>Drug Resistance, Microbial - genetics</topic><topic>Fluoroquinolones</topic><topic>Gemifloxacin</topic><topic>gyrA gene</topic><topic>Humans</topic><topic>Mechanisms of Action: Physiological Effects</topic><topic>Medical sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Mutation</topic><topic>Naphthyridines</topic><topic>Naphthyridines - pharmacology</topic><topic>parC gene</topic><topic>Pharmacology. Drug treatments</topic><topic>Streptococcus pneumoniae</topic><topic>Streptococcus pneumoniae - drug effects</topic><topic>Streptococcus pneumoniae - enzymology</topic><topic>Streptococcus pneumoniae - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HEATON, Victoria J</creatorcontrib><creatorcontrib>AMBLER, Jane E</creatorcontrib><creatorcontrib>FISHER, L. Mark</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Antimicrobial Agents and Chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HEATON, Victoria J</au><au>AMBLER, Jane E</au><au>FISHER, L. Mark</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Potent Antipneumococcal Activity of Gemifloxacin Is Associated with Dual Targeting of Gyrase and Topoisomerase IV, an In Vivo Target Preference for Gyrase, and Enhanced Stabilization of Cleavable Complexes In Vitro</atitle><jtitle>Antimicrobial Agents and Chemotherapy</jtitle><stitle>Antimicrob. Agents Chemother</stitle><addtitle>Antimicrob Agents Chemother</addtitle><date>2000-11-01</date><risdate>2000</risdate><volume>44</volume><issue>11</issue><spage>3112</spage><epage>3117</epage><pages>3112-3117</pages><issn>0066-4804</issn><eissn>1098-6596</eissn><coden>AACHAX</coden><abstract>Classifications
Services
AAC
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit
StumbleUpon
Twitter
current issue
AAC
About
AAC
Subscribers
Authors
Reviewers
Advertisers
Inquiries from the Press
Permissions & Commercial Reprints
ASM Journals Public Access Policy
AAC
RSS Feeds
1752 N Street N.W. • Washington DC 20036
202.737.3600 • 202.942.9355 fax • journals@asmusa.org
Print ISSN:
0066-4804
Online ISSN:
1098-6596
Copyright © 2014
by the
American Society for Microbiology.
For an alternate route to
AAC
.asm.org, visit:
AAC
</abstract><cop>Washington, DC</cop><pub>American Society for Microbiology</pub><pmid>11036032</pmid><doi>10.1128/AAC.44.11.3112-3117.2000</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0066-4804 |
| ispartof | Antimicrobial Agents and Chemotherapy, 2000-11, Vol.44 (11), p.3112-3117 |
| issn | 0066-4804 1098-6596 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72342314 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Anti-Infective Agents Anti-Infective Agents - pharmacology Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Biological and medical sciences Ciprofloxacin - pharmacology DNA Gyrase DNA Topoisomerase IV DNA Topoisomerases, Type II DNA Topoisomerases, Type II - drug effects DNA Topoisomerases, Type II - genetics DNA Topoisomerases, Type II - metabolism Drug Resistance, Microbial - genetics Fluoroquinolones Gemifloxacin gyrA gene Humans Mechanisms of Action: Physiological Effects Medical sciences Microbial Sensitivity Tests Mutation Naphthyridines Naphthyridines - pharmacology parC gene Pharmacology. Drug treatments Streptococcus pneumoniae Streptococcus pneumoniae - drug effects Streptococcus pneumoniae - enzymology Streptococcus pneumoniae - genetics |
| title | Potent Antipneumococcal Activity of Gemifloxacin Is Associated with Dual Targeting of Gyrase and Topoisomerase IV, an In Vivo Target Preference for Gyrase, and Enhanced Stabilization of Cleavable Complexes In Vitro |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T12%3A42%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Potent%20Antipneumococcal%20Activity%20of%20Gemifloxacin%20Is%20Associated%20with%20Dual%20Targeting%20of%20Gyrase%20and%20Topoisomerase%20IV,%20an%20In%20Vivo%20Target%20Preference%20for%20Gyrase,%20and%20Enhanced%20Stabilization%20of%20Cleavable%20Complexes%20In%20Vitro&rft.jtitle=Antimicrobial%20Agents%20and%20Chemotherapy&rft.au=HEATON,%20Victoria%20J&rft.date=2000-11-01&rft.volume=44&rft.issue=11&rft.spage=3112&rft.epage=3117&rft.pages=3112-3117&rft.issn=0066-4804&rft.eissn=1098-6596&rft.coden=AACHAX&rft_id=info:doi/10.1128/AAC.44.11.3112-3117.2000&rft_dat=%3Cproquest_pubme%3E17640422%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17640422&rft_id=info:pmid/11036032&rfr_iscdi=true |